These symptoms typically develop early in treatment and can dissipate with dose titration, administration of antiemetics, or slower dose escalation
Here is what attorneys typically gather before filing: Essential Records: Prescription records confirming use of Ozempic, Wegovy, or Rybelsus (pharmacy records, insurance EOB statements) Medical records showing the onset and diagnosis of your gastrointestinal or ophthalmic injury Gastric emptying study (scintigraphy) results for gastroparesis claims this is the gold-standard diagnostic test and is frequently requested during discovery Hospitalization records, emergency room visits, imaging scans, and lab results Records from gastroenterologists, ophthalmologists, or other specialists Documentation of any surgeries or procedures performed as a result of the injury (e.g., gallbladder removal, gastric stimulator implantation) Supporting Evidence: Timeline showing when you started the drug and when symptoms first appeared Documentation of all treating physicians and the treatments they recommended Records of lost income if your injury affected your ability to work Medical literature your treating physician referenced in forming your diagnosis One thing most people overlook: Attorneys in the Ozempic MDL have noted that some plaintiffs had a prior history of mild GI issues, which Novo Nordisk's defense teams use to argue that the drug was not the cause
Addressing Nutrition Gaps During GLP-1/GIP Therapy Experts have increasingly highlighted the importance of addressing nutritional deficiencies and muscle health challenges associated with GLP-1/GIP therapies
Different hormones constantly communicate with one another, influencing energy balance, glucose regulation, and endocrine responses
PMID 28405070
